© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
EDITORIAL
Why is a special section “Healthcare in Mainland
China” so crucial for HKMJ?
Jingchun Nie, PhD1; Yaojiang Shi, PhD1,2; Hao Xue, PhD1,2
1 Center for Experimental Education in Economics (CEEE), Shaanxi Normal University, Xi’an, Shaanxi, China
2 Section Editor, ‘Healthcare in Mainland China’, Hong Kong Medical Journal
Corresponding author: Dr Hao Xue (xuehjjx@gmail.com)
In order to promote high-quality research from
mainland China among medical professionals in
Hong Kong, the Hong Kong Medical Journal (HKMJ)
Editorial Board launched a Special Section titled
“Healthcare in Mainland China” in June 2021.1 We
hope that studies from mainland China in this special
section can speak to and shed light on healthcare in
other developing countries and regions, and provide
insight into Chinese healthcare practice for HKMJ’s
international readers.
For the past 2 years, coronavirus disease 2019
(COVID-19) has exerted a heavy burden on public
health worldwide, and there is an increasing body
of evidence reporting various effects and impacts
of COVID-19. However, few studies have provided
epidemiological and clinical characteristics of patients
affected at the early stage of the COVID-19 outbreak.
In this current issue of HKMJ under the
“Healthcare in Mainland China” section, Gao et al2
report a retrospective study that included laboratory-confirmed
96 cases of COVID-19 in a hospital in
Hangzhou City from 15 January 2020 to 30 March
2020. The authors investigated epidemiological,
demographic, clinical, radiological, and laboratory
features involving these cases; and found that,
during the early stage of the COVID-19 outbreak,
half of the patients were part of familial clusters.
Therefore, they suggested that strict prevention and
control measures during self-isolation should be
implemented. They also found that patients aged
>60 years with underlying co-morbidities were prone
to lymphocytopenia and severe infection.
China is the world’s most populous country,
and the large population presents numerous
healthcare issues. For example, China accounted for
24% of newly diagnosed cases and 30% of cancer-related
deaths worldwide in 2020.3 There were
also an estimated 93.8 million prevalent cases of
cardiovascular diseases overall during 2016 in China,
accounting for about 17.8% of the global burden.4 5
Moreover, nearly half of all vision problems among
children globally occur in China.6 To address such
a volume of challenges, China’s total healthcare
expenditure was >7.2 trillion yuan in 2020, with
>1.0 million clinics and hospitals, and >13.5 million
medical personnel.7 In addition, there is a significant income disparity between urban and rural areas and
between coastal and inland regions in mainland
China. All of these factors lead to a broad and diverse
wealth of healthcare research in the region.
We highly appreciate and sincerely welcome
more researchers and healthcare professionals to
submit their research on healthcare in mainland
China for consideration for publication in HKMJ.
The HKMJ review process is highly selective, and
only the highest quality submissions are accepted for
publication. We hope to promote global healthcare
improvement by providing our valued international
and local readers with high-quality research from
mainland China.
Author contributions
All authors contributed to the editorial, approved the final version for publication, and take responsibility for its accuracy
and integrity.
Conflicts of interest
The authors have declared no conflict of interest.
References
1. Shi YJ, Xue H, Wong MCS. Call for papers: special section
“Healthcare in Mainland China”. Hong Kong Med J
2021;27:174. Crossref
2. Gao J, Zhang S, Zhou K, Liu J, Pu Z. Epidemiological and
clinical characteristics of patients with COVID-19 from
a designated hospital in Hangzhou City: a retrospective
observational study. Hong Kong Med J 2022;28:54-63. Crossref
3. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing
profiles of cancer burden worldwide and in China: a
secondary analysis of the global cancer statistics 2020.
Chin Med J (Engl) 2021;134:783-91. Crossref
4. Li X, Wu C, Lu J, et al. Cardiovascular risk factors in China: a nationwide population-based cohort study. Lancet Public Health 2020;5:e672-81. Crossref
5. Liu S, Li Y, Zeng X, et al. Burden of cardiovascular diseases
in China, 1990-2016: findings from the 2016 Global Burden
of Disease Study. JAMA Cardiol 2019;4:342-52. Crossref
6. Resnikoff S, Pascolini D, Mariotti SP, Pokharel GP. Global
magnitude of visual impairment caused by uncorrected
refractive errors in 2004. Bull World Health Organ
2008;86:63-70. Crossref
7. Wang L, Chen Y. Determinants of China’s health
expenditure growth: based on Baumol’s cost disease
theory. Int J Equity Health 2021;20:213. Crossref